Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys

被引:27
作者
Cuker, Adam [1 ]
Raby, Anne [2 ]
Moffat, Karen A. [2 ,3 ,4 ]
Flynn, Greg [2 ]
Crowther, Mark A. [3 ,4 ]
机构
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Qual Management Program, Lab Serv, Toronto, ON, Canada
[3] McMaster Univ, Hamilton, ON, Canada
[4] St Josephs Hosp, Hamilton, ON, Canada
关键词
Heparin; activated partial thromboplastin time; anti-Xa; interlaboratory variation; PARTIAL THROMBOPLASTIN TIME; UNFRACTIONATED HEPARIN; THERAPEUTIC RANGE; DIFFERENT LOTS; APTT; REAGENTS; SENSITIVITY; ANTICOAGULANT; INVITRO; ASSAYS;
D O I
10.1160/TH10-02-0099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Unfractionated heparin (UFH) monitoring is subject to substantial interlaboratory variation. We analysed results of annual coagulation surveys administered by the Quality Management Program Laboratory Services (Toronto, ON, Canada) from 2003 to 2007 to evaluate variation in UFH monitoring across Ontario. Participating laboratories performed an activated partial thromboplastin time (APTT) utilising their local methodology on lyophilised human plasma spiked with UFH. In the 2006 and 2007 surveys, laboratories licensed to perform anti-Xa assays also reported anti-Xa activity results. The APTT differed significantly between heparin-sensitive and heparin-insensitive methods (p<0.0005). Within-method variation was observed and increased with increasing heparin concentration. Among laboratories performing an APTT and anti-Xa, the coefficient of variation was greater in the anti-Xa than in the APTT for both the 2006 (64.0% vs. 10.5%) and 2007 (15.0% vs. 11.6%) surveys. Substantial interlaboratory variation in UFH monitoring, both between and within APTT methods, was observed and was not reduced by use of an anti-Xa assay.
引用
收藏
页码:837 / 844
页数:8
相关论文
共 25 条
[1]   Guidelines on the use and monitoring of heparin [J].
Baglin, T ;
Barrowcliffe, TW ;
Cohen, A ;
Greaves, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (01) :19-34
[2]  
BAIN B, 1980, AM J CLIN PATHOL, V74, P668
[3]  
BANEZ EI, 1980, AM J CLIN PATHOL, V74, P569
[4]   PROSPECTIVE STUDY OF VALUE OF MONITORING HEPARIN TREATMENT WITH ACTIVATED PARTIAL THROMBOPLASTIN TIME [J].
BASU, D ;
CADE, J ;
GALLUS, A ;
HIRSH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (07) :324-+
[5]  
BRANDT JT, 1981, AM J CLIN PATHOL, V76, P530
[6]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[7]  
CHIU HM, 1977, BLOOD, V49, P171
[8]  
CROWTHER M, 2004, BROADSHEET APTT HEPA
[9]   Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time [J].
Cuker, A. ;
Ptashkin, B. ;
Konkle, B. A. ;
Pipe, S. W. ;
Whinna, H. C. ;
Zheng, X. L. ;
Cines, D. B. ;
Pollak, E. S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) :80-86
[10]   EFFECT OF CLOT-DETECTION METHODS AND REAGENTS ON ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) - IMPLICATIONS IN HEPARIN MONITORING BY APTT [J].
DANGELO, A ;
SEVESO, MP ;
DANGELO, SV ;
GILARDONI, F ;
DETTORI, AG ;
BONINI, P .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (03) :297-306